AstraZeneca’s Enhertu Wins Approval in EU by CHMP
27 Juni 2022 - 06:26PM
TipRanks
2 mutations who have HER2-negative high-risk early breast cancer
previously treated with neoadjuvant or adjuvant chemotherapy.
Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate
(ADC) being jointly developed and commercialized by Daiichi Sankyo
and AstraZeneca.
https://www.tipranks.com/news/astrazenecas-enhertu-wins-approval-in-eu-by-chmp?utm_source=advfn.com&utm_medium=referral
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jul 2022 bis Aug 2022
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Aug 2021 bis Aug 2022